BRIEF-Assembly Biosciences Provides Update On The Ongoing Phase 2 Extension Study Of Vebicorvir In Patients With Chronic Hepatitis B Virus Infection

Nov 5 (Reuters) - Assembly Biosciences Inc (ASMB):

* ASSEMBLY BIOSCIENCES PROVIDES UPDATE ON THE ONGOING PHASE 2 EXTENSION STUDY OF VEBICORVIR IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION

* ASSEMBLY BIOSCIENCES INC (ASMB) - STUDY HAS NOT ACHIEVED MEANINGFUL SVR RATES AS 39 OF 41 PATIENTS HAVE NOW RELAPSED

* ASSEMBLY BIOSCIENCES INC (ASMB) - AMONG PATIENTS WHO HAVE DISCONTINUED TREATMENT, 22 OF 23 WITH HBEAG NEGATIVE HBV HAVE RELAPSED

* ASSEMBLY BIOSCIENCES INC (ASMB) - EXPECTS TO INITIATE PHASE 3 CST TRIALS IN FIRST HALF OF 2021 IN COLLABORATION WITH BEIGENE FOR PARTNERED CHINA TERRITORY Source text for Eikon: Further company coverage: